NUVL Nuvalent, Inc.

Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.

$28.36  +0.74 (2.68%)
As of 03/27/2023 14:19:49 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/09/2017
Outstanding shares:  51,269,499
Average volume:  249,089
Market cap:   $1,428,880,937
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMVBZD3

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%